SAN DIEGO, Aug. 17 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received a Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI) under the agency's Streamlined Non-competing Award Procedures (SNAP). Under the SNAP procedures, both initial and follow-on grant requests are submitted and evaluated as one request. The initial grant award of $150,000 goes to support the manufacture and testing of the company's sarcoma vaccine currently in clinical testing. The follow-on grant application, for more than $1.5 million, can be funded under fast-track procedures following normal NCI reporting and review procedures.
"While the initial grant is modest, it is the critical gateway to substantially more funding that will offset patient and investigator expenses at the 12 investigative sites we have recruited for the Phase 2 clinical trial that is just getting underway," said David Hansen, CEO of MabVax. He added that "the SNAP program allows the company to submit a grant request that encompasses substantially more of the research project and potentially allows for more rapid funding of the entire grant request."
The sarcoma vaccine grant is intended to support the Phase II clinical trial that will enroll 134 metastatic sarcoma patients in a randomized, multicenter, double-blind study of the trivalent vaccine specifically developed to target and kill residual circulating cancer cells and micrometastases thought to cause recurrent cancer. In the United States (US), there are approximately 13,200 sarcoma cases diagnosed each year, representing less than 1% of all new cancers. Prognosis remains poor, with more than 5,200 patients in the US dying of disease each year. As in other malignancies, disease
|SOURCE MabVax Therapeutics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved